Guardant Health (GH) Q2 FY26 earnings call: guidance and Q&A

How will UnitedHealth Group coverage and ACS guidelines impact Shield's near-term volume and long-term ASP? What are the expectations for USPSTF's August meeting?

UnitedHealth coverage is expected to be a volume tailwind, helping to build commercial volume for younger patients. However, ASP realization will take time as negotiations and collection history are established. The company's expectations for USPSTF timing remain unchanged, despite some payers engaging in conversations earlier.

“This UHG win could actually give us some interesting benefits, like we are excited to see how the rest of the year would play out. It could be a tailwind for the volume. It would help us to strategically step-by-step build our commercial side of the volume, so not just 65 and above, but actually younger patients, make sure they get actually access to this breakthrough technology.”

asked by Kyle Mikson · answered by AmirAli Talasaz

What are the key drivers for the 50% Oncology volume growth guide, particularly for Reveal? How should we think about G360 volume growth given tough Q3 comps? How did the UnitedHealth coverage come about so unexpectedly?

Oncology volume growth is broad-based, with strong contributions from Guardant360 Liquid, Guardant360 Tissue, and Reveal. The company is confident in sustaining momentum despite tough comps. UnitedHealth coverage was unexpected but stemmed from a multi-year relationship and the value proposition of Shield; while other payers are engaging, no major wins are anticipated in the short term.

“Regarding UnitedHealth, it was unexpected for us too. It was much sooner than what we thought it's going to happen. Having said that, we have multiyear relationship with United because of our Oncology products and coverages.”

asked by Subhalaxmi Nambi · answered by AmirAli Talasaz

Given Guardant360's market presence, where is it on its growth S-curve, especially with the new Liquid CDx? What are the primary drivers for Shield's upside, and what sequential growth should be expected for Q3/Q4?

Guardant360 Liquid CDx, with its comprehensive genomic and epigenomic content, is still early in its potential, with future growth expected from multiple tests per patient. Shield's strong Q2 sequential growth was due to Quest co-promotion, DTC ads, and field force expansion. For Q3/Q4, a sequential growth of 12,000 tests quarter-over-quarter is a reasonable guide.

“So we don't expect multiple new things all hitting at once in Q3. Having said that, we are very excited of what we can do in the second half, like we increased our guide by 40,000 samples, which translates at the midpoint, the guide that we put out there, like sequential growth of 12,000 Q-over-Q.”

asked by Puneet Souda · answered by AmirAli Talasaz

What is the expected ADLT price for Guardant360, and how will it impact realized ASP? What portion of the incremental revenue from ADLT pricing will drop to the bottom line versus being reinvested?

The expected ADLT price for Guardant360 is $8,455, which could lead to a long-term realized ASP of around $5,000 (taking 12-24 months for commercial/MA payers to align). The incremental gross profit will be a mix: some will drop to the bottom line to accelerate the path to cash flow breakeven (currently end of 2027), and some will be reinvested in innovation and commercial operations.

“I think with Oncology, if and when we do get a higher ASP and incremental gross profit, we will allow some of that to drop down to the bottom line. I think we've said it many times, but we're very focused on getting to cash flow breakeven as quickly as possible.”

asked by Daniel Brennan · answered by Michael Bell

How are therapy monitoring volumes tracking for Reveal, and what is the revenue opportunity once reimbursement is secured? Has the FDA approval for Guardant360 Liquid CDx significantly impacted volumes yet?

Therapy monitoring for Reveal is seeing very good uptake and is viewed as a multi-million test annual opportunity, potentially as large as the MRD opportunity, especially once reimbursement is secured. The FDA approval for Guardant360 Liquid CDx occurred late in the quarter, so it's too early to see a material volume uplift, especially with a phased rollout, but positive reception is noted.

“If you think about it, there are 1 million late-stage patients. It's a multi-multimillion sort of testing opportunity there just for therapy monitoring if you think about monitoring those patients a couple of times during each course or each line of therapy.”

asked by Casey Woodring · answered by Helmy Eltoukhy

With positive FDA data points and lower COGS for Shield, how is the company thinking about profitability and the potential for an EBITDA breakthrough in the next 12 months?

The company is highly focused on achieving cash flow breakeven by the end of 2027. The non-Screening business is already adjusted EBITDA positive. While heavy investments in Screening commercial infrastructure continue, critical mass is expected in 2027, leading to leverage. ADLT designation for Guardant360 could accelerate the path to breakeven and profitability.

“We're well on track to get to cash flow breakeven by the end of 2027. And if you look at the business, excluding Screening, actually, that business now is adjusted EBITDA positive. It's generating positive cash flow.”

asked by Bradley Bowers · answered by Michael Bell

What are the expectations for MolDX decisions on Reveal indications, particularly for breast and IO? Can you provide details on the development work for the lower-COGS Shield workflow, specifically regarding methylation-only focus?

The company is hopeful for MolDX approval for breast cancer surveillance and immuno-oncology monitoring for Reveal by the end of 2026, with chemotherapy monitoring also progressing. The lower-COGS Shield workflow focuses on methylation-only, leveraging information from the current Shield V1, with algorithm updates and multimodal approaches expected to drive future performance improvements.

“I mean, certainly, IO and breast are probably the closest to the finish line. I think we're hopeful that we can get at least one or both of them by end of this year. And obviously making some good progress in chemo as well.”

asked by Catherine Ramsey · answered by Helmy Eltoukhy